search
Back to results

Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy

Primary Purpose

Epilepsy, Post-Traumatic

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
[18F]DPA-714 Positron Emission Tomography Scan
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Epilepsy, Post-Traumatic focused on measuring neuroinflammation, activated microglia, TSPO, Traumatic Brain Injury, TBI, Positron emission tomography

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Acute Traumatic Brain Injury (TBI)
  • Age 18-100 are eligible
  • Glasgow Coma Scale (GCS) 3-13 without continuous sedation at time of enrollment
  • Ability to enroll within 72 hours of injury
  • Hemorrhagic contusional injuries to frontal and/or temporal lobes.
  • Polytrauma including long bone fractures, blunt trauma, abdominal trauma or similar will be allowed
  • Penetrating TBI if continuous electroencephalography (cEEG) is feasible and survival for 2 years is feasible, recognizing that MRI may not be feasible with some forms of penetrating trauma

Exclusion Criteria:

  • Low-affinity TSPO binding profile
  • Ages 17 years or younger
  • Patients with diffuse axonal injury in the absence of hemorrhagic contusions or skull fracture, and isolated epidural hemorrhages that improve after evacuation
  • No planned continuous EEG monitoring during injury day 1-7
  • Inability to undergo MRI at 14 days (± 4 days) due to bullet, metal implant, or pacemaker
  • Pregnancy
  • Pre-existing Neurodegenerative Disorders
  • Pre-existing epilepsy/seizure disorder
  • Pre-existing dementia
  • Isolated anoxic brain injury
  • Incarceration present or pending
  • Devastating cervical spine injury

Sites / Locations

  • University of California, DavisRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Moderate to Severe Traumatic Brain Injury

Arm Description

All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.

Outcomes

Primary Outcome Measures

Quantification of [18F]DPA-714 binding in the brain following moderate to severe traumatic brain injury
Quantification of [18F]DPA-714 binding in the brain following moderate to severe traumatic brain injury

Secondary Outcome Measures

Frequency of early seizures, epileptiform discharges, and post-traumatic epilepsy
Modified Rankin Scale
All patients will undergo a phone survey at 3 and 6 months post-injury to assess functional outcome using the Modified Rankin Scale. The Modified Rankin Scale measures the degree of disability or dependence in daily activities of patients who have suffered an neurological injury, ranging from 0 (no symptoms) to 6 (dead).
Quantify the association between contusion volume and adjacent cerebral edema with [18F]DPA-714 binding on PET scans
All patients will undergo multi-modal MRI brain (Fluid-attenuated inversion recovery (FLAIR), susceptibility weighted imaging(SWI), diffusion weighted imaging(DWI)) two weeks post-injury to assess for acute structural abnormalities

Full Information

First Posted
June 24, 2019
Last Updated
July 6, 2022
Sponsor
University of California, Davis
search

1. Study Identification

Unique Protocol Identification Number
NCT03999164
Brief Title
Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy
Official Title
Imaging of Glial Activation and Risk for Post-Traumatic Epilepsy
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2020 (Actual)
Primary Completion Date
August 14, 2023 (Anticipated)
Study Completion Date
August 14, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Davis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study plans to evaluate the time course of inflammation in the brain after a moderate to severe traumatic brain injury using positron emission tomography (PET) brain imaging. Patients will undergo PET scans of the brain at two weeks and two months after injury to measure neuro-inflammation. The results of the PET scans will be analyzed and correlated with the risk of post-traumatic epilepsy.
Detailed Description
The development of post-traumatic epilepsy (PTE) is associated with neurobiological, cognitive, psychological, and social consequences that are far-reaching for the patient. Despite our keen awareness of this significant public health issue, little is known regarding the biological mechanisms leading to PTE. One plausible mechanism is that unchecked neuroinflammation, a process that occurs in animal and human models of both traumatic brain injury (TBI) and epilepsy, leads to altered synaptic transmission and neuronal excitability. However, the direct relationship between neuroinflammation and PTE has been difficult to ascertain from pre-clinical studies as they may not accurately reflect the human condition, as few animal models can induce the progression of PTE without a pharmacological enhancer and are predominately limited to studies of mild-to-moderate TBI given high animal mortality rates from more severe injuries. Measurements of neuroinflammation in human TBI and epilepsy has also proven difficult without invasive monitoring or post-mortem evaluations, and measurements of inflammatory mediators in blood or serum may not meaningfully reflect the extent of neuroinflammation. Encouragingly though, positron emission tomography (PET) can be used to measure the degree of in vivo glial activation in the central nervous system through radiotracer binding of the translocator protein (TSPO), serving as a surrogate of neuroinflammation. Minimally expressed in the uninjured brain, TSPO binding is increased in a number of brain disorders associated with neuroinflammation, including Alzheimer's disease, ischemic stroke, recurrent head trauma in football, brain metastases, TBI, and epilepsy, and is expressed predominately by activated microglia, the main mediators of neuroinflammation. Currently, no pre-clinical or clinical study has analyzed the relationship between glia activation, as measured by TSPO PET, and the risk for developing PTE. Accordingly, we plan to use [18F]DPA-714 to characterize neuro-inflammation following moderate-to-severe TBI in order to better understand the temporal time course of neuro-inflammation following injury and its potential role in epileptogenesis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy, Post-Traumatic
Keywords
neuroinflammation, activated microglia, TSPO, Traumatic Brain Injury, TBI, Positron emission tomography

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Moderate to Severe Traumatic Brain Injury
Arm Type
Experimental
Arm Description
All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
Intervention Type
Drug
Intervention Name(s)
[18F]DPA-714 Positron Emission Tomography Scan
Intervention Description
All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
Primary Outcome Measure Information:
Title
Quantification of [18F]DPA-714 binding in the brain following moderate to severe traumatic brain injury
Time Frame
2 weeks
Title
Quantification of [18F]DPA-714 binding in the brain following moderate to severe traumatic brain injury
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Frequency of early seizures, epileptiform discharges, and post-traumatic epilepsy
Time Frame
Admission - two years
Title
Modified Rankin Scale
Description
All patients will undergo a phone survey at 3 and 6 months post-injury to assess functional outcome using the Modified Rankin Scale. The Modified Rankin Scale measures the degree of disability or dependence in daily activities of patients who have suffered an neurological injury, ranging from 0 (no symptoms) to 6 (dead).
Time Frame
3 and 6 months
Title
Quantify the association between contusion volume and adjacent cerebral edema with [18F]DPA-714 binding on PET scans
Description
All patients will undergo multi-modal MRI brain (Fluid-attenuated inversion recovery (FLAIR), susceptibility weighted imaging(SWI), diffusion weighted imaging(DWI)) two weeks post-injury to assess for acute structural abnormalities
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute Traumatic Brain Injury (TBI) Age 18-100 are eligible Glasgow Coma Scale (GCS) 3-13 without continuous sedation at time of enrollment Ability to enroll within 72 hours of injury Hemorrhagic contusional injuries to frontal and/or temporal lobes. Polytrauma including long bone fractures, blunt trauma, abdominal trauma or similar will be allowed Penetrating TBI if continuous electroencephalography (cEEG) is feasible and survival for 2 years is feasible, recognizing that MRI may not be feasible with some forms of penetrating trauma Exclusion Criteria: Low-affinity TSPO binding profile Ages 17 years or younger Patients with diffuse axonal injury in the absence of hemorrhagic contusions or skull fracture, and isolated epidural hemorrhages that improve after evacuation No planned continuous EEG monitoring during injury day 1-7 Inability to undergo MRI at 14 days (± 4 days) due to bullet, metal implant, or pacemaker Pregnancy Pre-existing Neurodegenerative Disorders Pre-existing epilepsy/seizure disorder Pre-existing dementia Isolated anoxic brain injury Incarceration present or pending Devastating cervical spine injury
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ryan M Martin, MD
Phone
9167343650
Email
rymartin@ucdavis.edu
Facility Information:
Facility Name
University of California, Davis
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ryan Martin, MD
Phone
916-734-6518
Email
rymartin@ucdavis.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy

We'll reach out to this number within 24 hrs